Apoptose

Zaptuzumab (AD5-10) is a humanized monoclonal antibody targeting death receptor 5 (DR5) with high selective binding affinity. It specifically induces cancer cell death through caspase-mediated apoptosis and autophagic cell death (ACD). Zaptuzumab can activate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Additionally, it induces reactive oxygen species (ROS) production and reduces glutathione (GSH) levels. In various xenograft mouse tumor models, Zaptuzumab has demonstrated significant tumor growth inhibition and favorable safety profiles.

AM0001 is a human monoclonal antibody (mAb) that targets PDCD1/PD-1/CD279. It is applicable in cancer research.

VEGFR-2-IN-50 (Compound 10f) is a VEGFR-2 inhibitor and apoptosis inducer with an IC50 of 0.33 μM. It exhibits growth inhibitory activity against the MCF-7 and MDA-MB-231 breast cancer cell lines, with IC50 values of 19.86 μM and 10.88 μM, respectively, making it a promising agent for breast cancer research.

GPX4-AUTAC is an autophagy-mediated degrader (AUTAC) targeting GPX4. It consists of the inhibitor ML162-yne, a degradation tag FBnG, and a glycol linker. GPX4-AUTAC facilitates the ubiquitination of GPX4 by the E3 ligase TRAF6 and enhances its interaction with GPX4 and p62, leading to selective autophagy-dependent degradation of GPX4. This compound significantly induces ferroptosis and demonstrates potent anticancer activity in breast cancer cells, patient-derived organoids (PDOs), and MDA-MB-231 tumor xenograft mouse models. It shows strong synergy when used in combination with Sulfasalazine (SAS) or chemotherapy drugs (Paclitaxel or Cisplatin).

(GalNAc)3-CPT is a glycan-conjugated prodrug that targets the asialoglycoprotein receptor (ASGR) overexpressed on liver cells. It demonstrates significant antitumor activity by activating the cGAS-STING pathway and promoting CD8+ T cell infiltration into tumor sites, leading to apoptosis of tumor cells. In HepG2 cells, it shows an IC50 value of 3.07 μM.

Eps8 peptide 327 is an HLA-A*2402-restricted peptide antigen derived from the Eps8 protein. It exhibits potent antitumor activity and significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cell proliferation, induces apoptosis, and disrupts the EGFR signaling pathway by inhibiting the expression of downstream signals such as IL-2, TNF-α, and IFN-γ, as well as impeding the Eps8/EGFR interaction. It significantly suppresses tumor growth in HT-29 xenograft models.

GLPG4970 is a potent, selective, orally active dual inhibitor of salt-inducible kinases 2 and 3 (SIK2/SIK3), with IC50 values of 0.3 nM and 0.7 nM, respectively. It exhibits weak inhibition of the hERG channel, with an IC50 value of 29 μM. GLPG4970 reduces the release of tumor necrosis factor α (TNFα) and increases the release of interleukin 10 (IL-10). This compound is applicable for research in inflammation and immunology, such as studies on colitis.

L-Glutamic-5-14C acid is a bioactive chemical.

dPDL1-4 is a potent and selective eHSPTAC eHSP90PD-L1 degrader, with DC50 values of 7.77 μM (HeLa) and 6.52 μM (B16F10). It links eHSP90 to target proteins, inducing lysosomal degradation. dPDL1-4 effectively degrades PD-L1 and inhibits tumor growth, making it useful for research in cervical cancer and melanoma.

PI3Kδ-IN-25 is an orally active and selective PI3Kδ inhibitor with an IC50 of 2.1 nM. It exhibits IC50 values of 272, 285, and 1171 nM for PI3Kα, PI3Kγ, and PI3Kβ, respectively. In B16F10 cells, PI3Kδ-IN-25 inhibits the phosphorylation of AKTSer473, suppresses Treg cell proliferation, and downregulates the expression of PD-L1. In mouse models of B16F10 melanoma and Lewis lung cancer, PI3Kδ-IN-25 demonstrates anticancer activity by reducing tumor-infiltrating Treg cells and enhancing immune responses. This compound is applicable for research on cancers such as melanoma and lung cancer.

JAK-IN-40 (Compound 46) is an inhibitor of JAK, effectively targeting JAK1, JAK2, and JAK3 with IC50 values of 0.022, 0.759, and 1.601 μM, respectively. It reduces the phosphorylation of STAT3 and inhibits the proliferation of cancer cells Ba/F3 and JAK1-TEL Ba/F3 with GI50 values of 0.614 μM and 0.193 μM. JAK-IN-40 arrests cell cycle progression at the G2/M phase in H1975 and H2087 cells, leading to apoptosis. Additionally, JAK-IN-40 exhibits a synergistic anti-tumor effect when used in combination with Osimertinib.

[Ru(DIP)2TAP]Cl2, a Ruthenium(II) polypyridyl compound, serves as a photosensitizer and is utilized in photodynamic therapy (PDT) research.

Biotin-DEVD-CHO (TFA) is the biotin-conjugated form of the caspase-3 and caspase-7 inhibitor Ac-DEVD-CHO. It can be utilized for affinity purification of active caspase-3, -6, -7, and -8 and is also applicable for in vitro detection of active caspase-3.

VEGFR-2-IN-61 (Compound 7b) is an inhibitor of VEGFR-2 with an IC50 of 2.83 µM. It effectively inhibits the proliferation of various cancer cells, including MCF-7 cells, with an IC50 of 2.12 µM. Additionally, VEGFR-2-IN-61 suppresses cell migration and induces oxidative stress and apoptosis in MCF-7 cells.

DP-15 acts as a degrader of GSPT1 and BRD4, with DC50 values of 5.25 nM and 0.48 nM, respectively. This compound exhibits antiproliferative activity in AML and NHL cells, showing IC50 values in the nanomolar range, induces G1 phase cell cycle arrest, and triggers apoptosis in MOLM13 cells. Additionally, DP-15 demonstrates anti-leukemic properties in the MOLM-13 xenograft mouse model. [Pink: ligand for target protein JQ-1 carboxylic acid; Black: linker; Blue: ligand for E3 ligaseCereblonThalidomide-5-OH]

Y2641, a tetrahydro β-carboline derivative, is an orally active dual inhibitor of RANKL and TNF-α, with Kd values of 3.984 μM and 18.59 μM respectively. It suppresses RANKL-induced osteoclastogenesis and exhibits anti-inflammatory and cartilage-protective properties. Y2641 is applicable in osteoarthritis research.

Conjugated PUFA in C. officinalis oil, anticancer, inhibits Caco-2 growth and PG biosynthesis, induces DLD-1 apoptosis.

GNE-1567 is a potent ERα PROTAC degrader and a selective antagonist of XIAP, with a Kd of 0.03 μM. It is applicable in breast cancer research.

Diafenthiuron is a widely utilized thiourea-based pesticide that effectively hinders mitochondrial activity in insect pests.

(+)-Mcl-1 inhibitor 21 (Example 1-37) is a chemical compound that acts as an Mcl-1 inhibitor with an IC50 value of 172 nM. It demonstrates pro-apoptotic and antiproliferative activities in SUDHL5 and SUDHL10 cell lines, making it useful for cancer research.

WH244 is a second-generation dual degrader (PROTAC) targeting BCL-2 and BCL-xL proteins. It effectively degrades these proteins with high specificity, exhibiting a DC50 of 0.6 nM for BCL-xL and 7.4 nM for BCL-2. By promoting ubiquitination and subsequent proteasomal degradation of these proteins, WH244 restores apoptotic pathways in cells. The compound shows strong antitumor activity.

HMGB1-IN-2 (compound 15) is a selective inhibitor of the highly conserved nuclear protein HMGB1, demonstrating no inhibitory effect at an IC50 of 20.2 μM in

TopoisomeraseIIα-IN-10 (Compound 13r) is a topoisomerase IIα inhibitor that binds to the active site of DNA when complexed with topoisomerase IIα. This binding is stabilized through interactions with DNA base pairs and amino acid residues. By intercalating into DNA, TopoisomeraseIIα-IN-10 induces apoptosis and disrupts the mitochondrial membrane potential in HCT116 cells, effectively inhibiting their growth with an IC50 of 4.37 μM. It is applicable for cancer research studies.

PROTACPI3Kδ degrader-1 is a covalent PI3Kδ-targeting PROTAC degrader that targets lysine, with a DC50 of 3.98 nM. It exhibits potent antiproliferative activity and selective PI3Kδ inhibition (IC50: 8 nM). Additionally, PROTACPI3Kδ degrader-1 effectively degrades p-AKT, induces cell cycle arrest in the G1 phase, and promotes apoptosis and autophagy. It also significantly suppresses tumor growth in the SU-DHL-6 xenograft mouse model.

M7GpppAmpG is a trinucleotide 5′ cap analog, exhibiting capping efficiencies of 90% for the produced RNAs [1].

Thujopsene, a sesquiterpene found in T. dolabrata, exhibits a wide range of biological activities. It inhibits Na+/K+-ATPase and cytochrome P450 (CYP) isoform CYP2B6 with IC50 values of 25.9 µg/ml and Ki of 0.8 µM, respectively. Additionally, thujopsene demonstrates antimicrobial efficacy against both Gram-positive and Gram-negative bacteria, such as S. aureus, M. luteus, and S. typhimurium, with MICs ranging from 25-50 µg/ml. It also suppresses antigen-induced β-hexosaminidase release in IgE-sensitized RBL-2H3 mast cells (IC50= 25.1 µM) and shows cytotoxicity against A549 non-small cell lung cancer cells with an LC50 of 35.27 µg/ml. Furthermore, thujopsene causes mortality in mites D. farinae and T. putrescentiae, with LC50s of 9.82 and 10.92 µg/cm2, respectively.

1R,3R-RSL3 is a negative control for1S, 3R-RSL3.

IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. It completely inhibits CD73 enzymatic activity without causing a hook effect. IBI-325 can reverse adenosine monophosphate-mediated immunosuppression and significantly inhibits T cell proliferation and the release of cytokines (IL-2, IFN-γ, and TNF-α). In both hPBMC-reconstituted mouse models and hCD73 knock-in mouse models, IBI-325 demonstrates potent antitumor activity. This compound is applicable for cancer immunotherapy research.

GSNOR-IN-1 is a prodrug of GSNOR-IN-2 and functions as an S-nitrosoglutathione reductase (GSNOR) inhibitor capable of crossing the blood-brain barrier. GSNOR-IN-1 offers significant protective effects against damage induced by oxygen-glucose deprivation/reoxygenation (OGD/R). It regulates calcium signaling and synaptic function through Clstn1 S-nitrosylation and inhibits neuronal apoptosis. Additionally, GSNOR-IN-1 markedly reduces infarct volume in rat models of ischemic stroke while enhancing neurological function. With its neuroprotective properties, GSNOR-IN-1 holds potential for ischemic stroke research.

PROTAC Bcl-xL ligand-1 serves as a ligand targeting Bcl-xL, essential in synthesizing PROTACs [1].

ROTACMNK1degrader-1 is a selective MNK1 PROTAC degrader with a DC50 of 11.92 nM and a Dmax greater than 96% in MV4-11 cells. It significantly reduces p-eIF4E levels with an IC50 of 22.07 nM, induces apoptosis, and causes cell cycle arrest at the G1 phase. This compound exhibits potent antitumor activity, demonstrating strong anti-leukemic effects in MV4-11 xenograft mouse models with acceptable drug safety.

Antitumor agent-36: potent anti-cancer; causes DNA damage, triggers apoptosis, enhances immune response by upregulating T cells.

Potent PROTAC degrader for FLT3/CDK9, induces apoptosis, and shows promise for FLT3-ITD mutated AML research.

OICR12694 (JNJ-65234637) TFA, an orally active B cell lymphoma 6 (BCL6) inhibitor [1], demonstrates effectiveness in targeting BCL6 pathways.

Milademetan tosylate hydrate, an oral MDM2 inhibitor targeting AML and solid tumors, induces G1 arrest and apoptosis.

Chloranthalactone B, a sesquiterpenoid from Sarcandra glabra, inhibits inflammation via AP-1 & p38 MAPK.

DMUP inhibits CD47-SIRPα, induces apoptosis, boosts macrophage activity in A549 cells, and has antitumor properties.

Thalidomide-based E3 ligase ligand for PROTAC degrader MI-389 synthesis, linked to cereblon and Boc.

ERK-IN-6, a potent agent, inhibits ESCC growth and induces apoptosis through the ERK pathway.

Thalidomide derivative for CRBN protein recruitment, used in PROTACs production for protein degradation.

Antitumor Agent-64 (Compound 8d), a diosgenin derivative, exhibits potent cytotoxic activity against the A549 cell line and induces apoptosis in A549 cells

CDK8-IN-13 is a CDK8 inhibitor (IC50: 51.9 nM) with potent, selective and oral activity.

TRAP-1 (XJZ-06-462) is a p53 transcription activator that effectively activates mutant p53 and triggers the transcription of p53 target genes. In the p53Y220C pancreatic cell line, TRAP-1 rapidly upregulates p21 and other p53 target genes. TRAP-1 also inhibits cell proliferation, exhibiting IC50 values of 3.94 μM and 0.531 μM in BxPC-3 and A549 cell lines, respectively. Additionally, TRAP-1 modulates autophagy in lung cancer cells and provides protection against oxidative stress and apoptosis.

CQ-Mito, a derivative of CQ, demonstrates excellent phototherapeutic efficacy with a PI value of 167. This compound induces cell death through mechanisms such as apoptosis and ferroptosis. It mediates mitochondrial dysfunction, characterized by alterations in mitochondrial morphology and loss of MMP. Additionally, CQ-Mito effectively inhibits tumor growth in 3D multicellular tumor spheroid models.

PROTAC HIF-1α degrader-1 (compound V2) is an effective proteolysis-targeting chimeric (PROTAC) degrader of hypoxia-inducible factor-1α (HIF-1α), with an IC50 value of 7.54 µM. This compound exhibits anti-proliferative activity, reduces HIF-1α protein expression, and induces apoptosis.

NDI-Lyso is an anticancer agent targeting lysosomes, functioning through an enzyme-induced self-assembly (EISA) mechanism catalyzed by Cathepsin B. In cancer cell lysosomes, it forms rigid long fibers, promoting lysosomal swelling, lysosomal membrane permeabilization (LMP), and membrane disruption. This leads to non-classical caspase-independent apoptosis (Apoptosis). NDI-Lyso demonstrates significant selective anticancer activity across various cancer cell lines and drug-resistant cancer cells (IC50 approximately 10 μM), while exhibiting low toxicity to normal cells (IC50 > 60 μM).

Tripchlorolide is a useful organic compound for research related to life sciences and the catalog number is T126047.

Bromoiodoacetamide (I-HAcAm): cytotoxic, induces ROS & apoptosis in HepG-2 cells.

KP1019 is now discontinued.

12-HETE ((±)12-HETE) is a regulator of PGE2, having both antithrombotic and prothrombotic effects.

eIF4A3-IN-7: Potent eIF4A3 inhibitor, potential cancer/dysproliferation research (WO2019161345A1, Compound 8).

D-Trimannuronic acid from seaweed induces TNF-α in mouse macrophages; useful in pain, dementia studies.

Bcl-2-IN-4: potent, selective, oral Bcl-2 inhibitor with 1.5 nM IC50, >200x selectivity over Bcl-xL.

PDE4-IN-1 is a PDE4 inhibitor characterized by high potency (IC50: 8.6 nM) and superior selectivity over other PDE subtypes. This compound inhibits the release of inflammatory cytokines and chemokines. Additionally, PDE4-IN-1 significantly restores the damaged cAMP-CREB signaling pathway, inhibits proliferation, and promotes differentiation to reverse psoriasis formation.

Kdo2-Lipid A ammonium (KLA) is a selective and potent TLR4 agonist, a lipopolysaccharide.Kdo2-Lipid A ammonium induces the release of TNF and PGE2.

Dynorphin A is a endogenous opioid peptide and a κ-opioid receptor (KOR) agonist,a neurotransmitter and regulator in the central and peripheral nervous systems

Thalidomide-O-amido-PEG4-propargyl is a polyethylene glycol (PEG)-based linker employed for the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Flavopiridol (Alvocidib) blocks CDK1/2/4/6 by competing with ATP (IC50 ~40 nM); 7.5x selectivity over CDK7; also inhibits EGFR, PKA. In Phase 1/2 trials.

SSE1806, a podophyllotoxin derivative (a natural antimitotic agent), functions as a microtubule/tubulin inhibitor, exhibiting potent anticancer and

W1131 TFA is a STAT3 inhibitor and ferroptosis inducer that regulates the IL6-JAK-STAT3 and ferroptosis pathways,gastric cancer.

Tetrathiomolybdate (TM) promotes the dimerization of the metal-binding domain (WLN4) of the cellular copper efflux protein ATP7B through its characteristic

ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor that binds to ROR1's extracellular Frizzled domain, effectively inhibiting aberrant

KH16 is an HDAC inhibitor.KH16 stimulates apoptosis and is able to inhibit gene expression patterns in a variety of tumor cells.

TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor exhibiting a dissociation constant (K D) of 12.06 μM.

PROTAC GPX4 degrader-3 is a potent GPX4-targeting PROTAC degrader, exhibiting a DC50 of 0.019 μM (24 h) and an IC50 of 0.024 μM in HT1080 cells.

5-Aminolevulinic acid-13C-1 (5-ALA-13C-1) hydrochloride is the 13C-labeled form of 5-Aminolevulinic acid hydrochloride. 5-Aminolevulinic acid hydrochloride (5-ALA hydrochloride) serves as an intermediate in the biosynthesis of heme within the body and acts as a precursor to tetrapyrroles.

LL-K9-3, a selective hydrophobic tagging technology (HyT)-based degrader, specifically targets the CDK9-cyclin T1 complex, displaying DC50 values of 589 nM for

BODIPY FL thalidomide is a fluorescent probe that binds human cereblon protein with high affinity, exhibiting a dissociation constant (Kd) of 3.6 nM [1].

Fac-[Re(CO)3(L3)(H2O)][NO3] (Compound 3), a rhenium(I) tricarbonyl aqua complex, acts as an anticancer agent through the induction of mitochondrial dysfunction.

Thalidomide-Piperazine 5-fluoride hydrochloride, a derivative of the cereblon (CRBN) inhibitor Thalidomide, serves as a ligand for E3 ubiquitin ligase (Ligands for E3 Ligase), facilitating the synthesis of PROTACs [1].

Adenosine-d13 (Adenine riboside-d13; D-Adenosine-d13) is a deuterium-labeled form of Adenosine. Adenosine (Adenine riboside) is a widely present endogenous secretion that exerts effects via four G-protein-coupled receptors (A1, A2A, A2B, and A3). It influences nearly all aspects of cellular physiology, including neuronal activity, vascular function, platelet aggregation, and blood cell regulation.

FerroLOXIN-1 is a potent inhibitor of 15LOX-2, selectively blocking the production of ferroptosis-promoting HOO-ETE-PE and preventing RSL3-induced ferroptosis (ferroptosis). It interacts closely and specifically with 15LOX-2, particularly engaging with Y154, N155, and W158.

Cytarabine-d2 is the deuterated form of Cytarabine. Cytarabine is a nucleoside analog that induces cell cycle arrest at the S phase and inhibits DNA polymerase. It has an IC50 of 16 nM for inhibiting DNA synthesis and exhibits antiviral activity against HSV.

Cytostatin: Natural antitumor, inhibits cell adhesion, blocks B16 melanoma, induces apoptosis, selectively targets PP2A (IC50 = 29 nM).

Citric acid-d4-1 is a deuterium-labeled variant of citric acid. Citric acid functions as a preservative and food additive. It induces apoptosis in HaCaT cells, causing cell cycle arrest at the G2/M and S phases. Additionally, citric acid leads to hepatic oxidative damage by reducing antioxidant enzyme activity and exhibits nephrotoxicity in mice.

Rapamycin is a potent and specific mTOR inhibitor that suppresses mTOR in HEK293 cells with an IC50 of 0.1 nM. It binds to FKBP12, thereby inhibiting mTORC1. Additionally, Rapamycin serves as an autophagy (autophagy) activator and functions as an immunosuppressant.

Pitavastatin-d5 (sodium) is the deuterated form of Pitavastatin sodium. Pitavastatin (NK-104) sodium acts as a potent inhibitor of hydroxymethylglutaryl-CoA (HMG-CoA) reductase. In HepG2 cells, it inhibits cholesterol synthesis from acetate with an IC50 of 5.8 nM. Pitavastatin sodium is a highly effective inducer of hepatic low-density lipoprotein cholesterol (LDL-C) receptors.

2-Deoxy-D-glucose-d is the deuterated form of 2-Deoxy-D-glucose. This compound is a glucose analogue that acts as a glucose metabolism inhibitor by targeting hexokinase to hinder glycolysis.

Resveratrol-13C6 is a carbon-13 labeled form of Resveratrol. Resveratrol (trans-Resveratrol; SRT501) is a natural polyphenol known for its antioxidant, anti-inflammatory, cardioprotective, and anticancer properties. It targets a variety of proteins, including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, and DNA polymerase, and acts as a specific activator of SIRT1. Additionally, Resveratrol is an effective Pregnane X Receptor (PXR) inhibitor and serves as an Nrf2 activator, capable of mitigating aging-related progressive renal injury in mouse models. It also enhances nitric oxide (NO) production in endothelial cells.

Thiamine-d4 (hydrochloride) is the deuterated form of Thiamine (hydrochloride). Thiamine hydrochloride (Thiamine chloride hydrochloride) is an essential micronutrient, serving as a cofactor for numerous central metabolic enzymes.

Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody for the study of unresectable hepatocellular carcinoma (uHCC).

Rasagiline (AGN1135) is an inhibitor of monamine oxidase used as adjunctive therapy in combination with levodopa and carbidopa in the management of Parkinsons

Pipermethystine is a useful organic compound for research related to life sciences and the catalog number is T124340.

Giloralimab (ABBV-927) is a antibody targeting CD40 with anticancer activity for the study of triple-negative breast cancer and non-small cell lung cancer.

BMS-986156 is a fully humanized IgG1 agonist monoclonal antibody that targets the glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR). It binds to GITR and enhances the activation of T effector cells while deactivating T regulatory cells. BMS-986156 is applicable for research in advanced solid tumors.

Zigakibart (BION-1301) is a humanized monoclonal antibody targeting TNFSF13 with anti-inflammatory activity for the study of immunoglobulin A nephropathy (IgAN)

Tulinercept (OPRX-106), a monoclonal antibody, may be utilized in a range of biochemical research applications [1].

Lipustobart is an IgG4-kappa humanized monoclonal antibody targeting PDCD1 (programmed cell death 1, PD1, PD-1, CD279), with immunostimulant and antineoplastic

δ-secretase inhibitor 11 is an inhibitor of δ-secretase and can be used as a lead compound for translational development of AD treatment.

Diethanolamine hydrochloride is HSD17B4 (hydroxysteroid 17-beta dehydrogenase 4) and pregnane X receptor (PXR), p53 Estrogen receptor.

Mcl-1 Inhibitor 15 (Compound (Ra)-15), with a K i of 0.02 nM, is utilized in cancer research [1].

DEDN6526A (RG-7636) is a humanized ADC compound targeting endothelin B receptor (ETBR), which can be used to study melanoma.

CYP51/PD-L1-IN-3 (compound L21), a quinazoline with antifungal properties, serves as a dual inhibitor targeting CYP51 (IC50: 0.205 μM) and PD-L1 (IC50: 0.039 μM

Izuralimab is a bispecific IgG1 antibody that targets both the inducible T-cell costimulator (ICOS/CD278) and PD-1 [1].

FG-3019 (Pamrevlumab), a human antibody, targets CTGF, potentially treating idiopathic pulmonary fibrosis.

[1,1'-Biphenyl]-3-amine is an inhibitor of MAO-A and MAO-B and can inhibit the cell viability of HT-29, HEK 293, and MCF-7 cells.

Efaprimermin alfa (OMP-336B11) is a human monoclonal antibody that targets TNFRSF18, and functions as a GITR ligand-Fc fusion protein [1].

Latikafusp (AMG 256) is a fusion protein that is a PD-1 blocker and IL-21R agonist with antitumor activity.

Lenercept (Ro 45-2081) is a recombinant fusion protein combining the soluble TNF-receptor (p55) with the Fc portion of human IgG1 [1].